Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 12;61(50):e202211674.
doi: 10.1002/anie.202211674. Epub 2022 Nov 16.

Ruthenium-Based Metal-Organic Nanoradiosensitizers Enhance Radiotherapy by Combining ROS Generation and CO Gas Release

Affiliations

Ruthenium-Based Metal-Organic Nanoradiosensitizers Enhance Radiotherapy by Combining ROS Generation and CO Gas Release

Qixuan Dai et al. Angew Chem Int Ed Engl. .

Abstract

A lack of targeting accuracy and radiosensitivity severely limits clinical radiotherapy. In this study, we developed a radiosensitizer comprised of Ru-based metal-organic nanostructures (ZrRuMn-MONs@mem) to optimize irradiation by maximizing reactive oxygen species (ROS) generation and CO release in X-ray-induced dynamic therapy (XDT). The well-designed nanostructures increase the direct absorption of radiation doses (primary radiation) and promote the deposition of photons and electrons (secondary radiation). The secondary electrons were trapped and transferred in the constrained MONs where they induce a cascade of reactions to increase the therapeutic efficiency. Meanwhile, the full-length antiglypican 3 (GPC3) antibody (hGC33) expressed a cell membrane coating enabling active targeting of tumor sites with optimized biocompatibility. The ZrRuMn-MONs@mem represents a starting point for advancing an all-around radiosensitizer that operates efficiently in clinical XDT.

Keywords: Antitumor Agents; Gas Therapy; Metal-Organic Nanostructures; Radiotherapy; X-Ray-Induced Dynamic Therapy.

PubMed Disclaimer

References

    1. None
    1. H. H. W. Chen, M. T. Kuo, Oncotarget 2017, 8, 62742-62758;
    1. D. Schaue, W. H. McBride, Nat. Rev. Clin. Oncol. 2015, 12, 527-540.
    1. U. M. Cytlak, D. P. Dyer, J. Honeychurch, K. J. Williams, M. A. Travis, T. M. Illidge, Nat. Rev. Immunol. 2022, 22, 124-138.
    1. None

Publication types

LinkOut - more resources